The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials

The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials

We aimed to assess the association between the use of Glucagon-like peptide-1 receptor agonists and the risk of 12 respiratory diseases in patients with type 2 diabetes, obesity, or overweight. The PubMed (MEDLINE), EMBASE, Cochrane Library, and ClinicalTrials.gov databases were searched from the es...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetology and metabolic syndrome 2023-07, Vol.15 (1), p.164-21, Article 164
Hauptverfasser: Yu, Meixin, Wang, Ruxin, Pei, Ling, Zhang, Xiaofang, Wei, Jinjing, Wen, Yun, Liu, Han, Ye, Haowen, Wang, Jinghao, Wang, Lihong
Format: Artikel
Sprache:eng
Schlagworte:
Agonists
Asthma
Bias
Body weight
Bronchitis
Chronic obstructive pulmonary disease
Clinical trials
Cohort analysis
Comparative analysis
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes mellitus, type 2
Edema
GLP-1RA
Glucagon
Glucagon-like peptide 1
Hemoglobin
Hypoglycemic agents
Insulin
Lung diseases
Meta-analysis
Obesity
Overweight
Randomized controlled trial
Respiratory agents
Respiratory diseases
Respiratory illness
Sleep apnea
Type 2 diabetes
Weight control
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We aimed to assess the association between the use of Glucagon-like peptide-1 receptor agonists and the risk of 12 respiratory diseases in patients with type 2 diabetes, obesity, or overweight. The PubMed (MEDLINE), EMBASE, Cochrane Library, and ClinicalTrials.gov databases were searched from the establishment of the database to December 24, 2022. Dichotomous outcomes were analyzed using RR and 95% CI calculated from fixed-effects models. Twenty-eight RCTs were ultimately included for analysis, involving a total of 77,485 participants. Compared to controls, patients with GLP-1RAs have a 14% lower risk of respiratory disease (RR 0.86, 95% CI 0.81-0.93 p 
ISSN:1758-5996
1758-5996
DOI:10.1186/s13098-023-01118-6